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Background: Craniosynostosis is a developmental disorder characterized by the premature
fusion of skull sutures, necessitating repetitive, high-risk neurosurgical interventions
throughout infancy. This study used protein-releasing Titania nanotubular implant (TNT/
Ti) loaded with glypican 3 (GPC3) in the cranial critical-sized defects (CSDs) in Crouzon
murine model (Fgfr2c342y/+ knock-in mutation) to address a key challenge of delaying post-
operative bone regeneration in craniosynostosis.
Materials and methods: A 3 mm wide circular CSD was created in two murine models of
Crouzon syndrome: (i) surgical control (CSDs without TNT/Ti or any protein, n=6) and (ii)
experimental groups with TNT/Ti loaded with GPC3, further subdivided into the presence or
absence of chitosan coating (on nanotubes) (n=12 in each group). The bone volume percen-
tage in CSDs was assessed 90 days post-implantation using micro-computed tomography
(micro-CT) and histological analysis.
Results: Nano-implants retrieved after 90 days post-operatively depicted well-adhered,
hexagonally arranged, and densely packed nanotubes with average diameter of 120±10 nm.
The nanotubular architecture was generally well-preserved. Compared with the control bone
volume percentage data (without GPC3), GPC3-loaded TNT/Ti without chitosan coating
displayed a significantly lower volume percent in cranial CSDs (P<0.001). Histological
assessment showed relatively less bone regeneration (healing) in GPC3-loaded CSDs than
control CSDs.
Conclusion: The finding of inhibition of cranial bone regeneration by GPC3-loaded TNT/Ti
in vivo is an important advance in the novel field of minimally-invasive craniosynostosis
therapy and holds the prospect of altering the whole paradigm of treatment for affected
children. Future animal studies on a larger sample are indicated to refine the dosage and
duration of drug delivery across different ages and both sexes with the view to undertake
human clinical trials.
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Introduction
Craniosynostosis is a developmental disorder characterized by premature fusion of one
or more cranial sutures, affecting approximately 1 in 2,500 children.1–3
Craniosynostosis can result in severe complications, including increased intracranial
pressure, impaired cerebral blood flow, airway obstruction, restricted brain growth,
impaired vision and hearing, cognitive disability, seizure, and adverse psychological
effects associated with deformed craniofacial facial features.4–6 Management of cra-
niosynostosis usually requires complex cranial vault reconstruction to release the
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synostosed suture, and to correct craniofacial deformities, but
rapid post-operative bone re-growth at the craniectomy site
often necessitates repetitive high-risk neurosurgical proce-
dures as the dysmorphic growth continues.7
Recent advancements in cranial bone biology and genetic
micro-array techniques have unraveled the pathophysiology of
craniosynostosis by identifying biochemical pathways involved
in both normal and pathological suture morphogenesis.8,9 The
osteogenically potent bone morphogenetic protein 2 (BMP2)
signaling pathway plays a key role in regulating cellular func-
tions and bone formation around sutures, whereas defects in this
pathway have been linked to craniosynostosis.1,2Molecules that
inhibit bone formation (such as noggin and glypicans (GPC1
and GPC3)) downregulate the BMP2-mediated osteogenic
activity and are expressed in reduced amounts in prematurely-
fusing sutures.10 While noggin has been shown to inhibit bone
formation in animal models, its effect is only short-term and is
restricted to the initial phase of suture resynostosis.11,12
Furthermore, noggin therapy does not rescue premature suture
fusion in delayed-onset craniosynostosis.13 In comparison, gly-
picans have a longer-term potential in controlling post-operative
bone growth, with GPC3 being shown to bemore effective than
GPC1.14
Murine models of human craniosynostosis have elucidated
the phenotypic changes associated with specific genetic muta-
tions, eg, in Crouzon murine model linked to the Fgfr2c342y/+
mutation.15 For craniofacial application, a critical-sized defect
(CSD) is created surgically in themouse cranium that provides
a reproducible and non-load bearing orthotopic site for asses-
sing cranial bone regeneration. CSD resembles an operative
site in a human skull where a surgical cut is made into the
parietal bone to release synostosed (fused) sutures. As bone
formation is a continuous process, it is essential for the loca-
lized drug delivery system to provide a slow, sustained
(extended) release of glypicans.Moreover, the protein concen-
tration is critical as the heterogeneous suture cells can respond
paradoxically to the same biomolecule at different
concentrations.8 Localized drug delivery of GPC has been
recently demonstrated by our team for the first time using
Titanium (Ti) implants with a layer of Titania nanotubes
(TNTs) fabricated by electrochemical oxidation.16,17 This
drug delivery system has the potential to address a key clinical
challenge for craniosynostosis management in terms of devel-
oping a viable localized drug delivery system with desirable
pharmacokinetics and release pattern. Numerous in vitro stu-
dies (including cell studies) have demonstrated sustained
release of various drugs from TNTs for potential application
in neurodegenerative diseases (eg, neurotransmitters),18
orthopedics (eg, antibiotics, anti-inflammatory, and antiresorp-
tive agents),19,20 and cancer treatment (doxorubicin (DOX)
and apoptosis-inducing ligand).21 In addition, in vivo animal
studies have confirmed the biocompatibility and osseointegra-
tion properties of these implants.22,23
Cytokines and therapeutic proteins have been administered
locally into the craniofacial regions either directly using a
carrier (polymer-based microspheres, absorbable collagen
sponges, hydrogels, and implants, lipid nanoparticles, cera-
mics, titanium fibre-mesh or porous glass) or indirectly using
gene based therapies (both viral and non-viral vectors).8,24,25
Nonetheless, they lack therapeutic efficacy due to undesired
pharmacokinetics and uncontrolled release patterns, and/or are
very complex to formulate. TNTs are easy to fabricate and
provide superior control of release rate and duration over other
drug delivery methods.25,26 Recently, we have demonstrated
the use of Titania nanotubular implant (TNT/Ti) for sustained
delivery of GPC3 over a period of 2 weeks in vitro, with
improved (prolonged) release for chitosan coated TNT/Ti.16
These in vitro findings provide a strong foundation for further
testing of sustained-drug releasing capabilities of TNT/Ti in
vivo, which is an important step towards clinical translation.
Our aim was to assess the effect of GPC3 released from
TNT/Ti (with or without chitosan coating) in inhibiting cranial
bone regeneration in a Crouzon murine model involving ske-
letally-matured mice (3.0–3.5 months old) at 90-day post-
implantation period. The experimental design of in vivo pro-
tein release via TNT/Ti within the cranial critical-sized defects
is represented in Figure 1. We hypothesized that localized
release of GPC3 would inhibit bone formation in Crouzon
murine model of CSD during that period. To achieve this and
provide critical therapeutic concentration of GPC3 with sus-
tained release, we selected the anodization process to make
TNTs with large diameters and with higher drug loading capa-
city. Slow and sustained release of loaded GPC3 inside TNTs
for several weeks was tested by coating of layers of biodegrad-
able chitosan on the top of TNTs surface. To prove the pro-
posed hypothesis of inhibiting cranial bone regeneration using
GPC3 loaded TNTs implants, we performed aCrouzonmurine
model with 90-day post-implantation period combined with
histological and morphometric studies.
Materials and methods
Sample
Skeletally-matured male mice with a mixed C57BL/6 genetic
background were divided into two cohorts (Figure 2): mice
with Fgfr2c342y/+ knock-in mutation (representative of human
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Crouzon syndrome) (n=30) and wildtype littermates
(Fgfr2c342+/+) (n=16). They were obtained from an ongoing
breeding colony of craniosynostotic miceh at the Women’s
and Children’s Hospital, Adelaide. The mice were managed
using the existing protocol in a light- and temperature-con-
trolled, pathogen-free environment with unrestricted access to
water and food.Welfare assessment was carried out weekly by
visual examination. The animal experimentation protocol was
approved by the Women’s and Children’s Hospital, North
Adelaide (AE977/6/2014) and the Animal Ethics
Committees of the University of Adelaide, Adelaide (M-
2014–138). The animals were cared for in the animal facility
using the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes (7th Edition, 2004). For drug-
delivery, nanotubes were anodized on TNT/Ti (substrate) and
then loaded with either a non-functional protein (bovine serum
albumin (BSA) or an inhibitor of bone production, GPC3).
Study design
This study was conducted in two stages, one relating to each
cohort of mice (Figure 2). In the first stage, a wildtype “proof
of principle” study was carried out for feasibility testing of the
TNT/Ti drug delivery system (Figure 2A). This study was
necessary to confirm no foreign body reaction was triggered
by the TNT/Ti (eg, bone resorption), and to showGPC3would
inhibit bone growth more effectively than BSA. We included
two wildtype groups: (i) TNT/Ti loaded with (BSA), which
was subdivided into two groups (presence or absence of
chitosan coating on nanotubes; n=5 in each group), and (ii)
TNT/Ti loaded with inhibitor of bone production (GPC3)
without chitosan coating (n=6). This study also enabled chit-
osan coating on BSA release to be assessed, and some experi-
mental parameters to be refined for the Crouzon study. In the
second stage involving the Crouzon murine model, we
included two groups: (i) Surgical control (CSDs without
TNT/Ti or any protein, n=6) and (ii) Experimental groups
with TNT/Ti loaded with GPC3, subdivided into presence or
absence of chitosan coating (on nanotubes) (n=12 in each
group). Chitosan coating was included as a variable in the
Crouzon (in vivo) murine model because of our previous in
vitro finding of its potential to extend drug release from
nanotubes.16 All mice were divided into various groups ran-
domly. We only studied males in order to eliminate any
potential confounding effect of estrogen that affects bone
density and healing in females.
Intra- and post-operative digital photographs of both wild-
type and Crouzon skulls were obtained for visual analysis of
CSDs. Scanning electron microscopy (SEM) was used to
assess the implant morphology before and after the implanta-
tion period. High-resolution micro-CT imaging and 3D image
reconstruction yielded quantitative bone volume percentage
data in the non-mineralized medullary space of CSDs at day
90 (ie, 3 months) post-operatively. Qualitative histological
analysis of the craniectomy sites was carried out using
Haemotoxylin and Eosin (H&E) and Movat Pentachrome
staining to assess the quality of newly regenerated bone and

















Figure 1 An electrochemically anodized Titania nanotubular implant (TNT/Ti) for sustained delivery of a bone antagonizing protein (glypican 3, GPC3) and a control protein
(bone serum albumin; BSA) in surgically created critical-sized defect (CSD) as part of craniosynostosis therapy.
Abbreviations: Ti, titanium; TNT, Titania nanotube.
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Fabrication of TNT/Ti
High purity titanium foil (99.6% of Ti 0.20mm thickness) was
supplied by Nilaco (Japan). All standard electrolytes, poly-
mers, and solvents for TNT implant fabrication were obtained
from Sigma-Aldrich (Australia). Titanium foils were annealed
in air for 2 hours at 450°C, mechanically polished, cut into 3
mm circular Ti discs (via ultrasonic milling using DMG
Ultrasonic 20 linear) and cleaned/degreased by successive
sonication in acetone, ethanol, and isopropanol. Then, the
discs were rinsed with deionized water and dried with nitrogen
gas. TNT arrays on Ti discs were fabricated by using a mod-
ified two-step electrochemical anodization process in lactic
acid containing organic electrolyte (comprising of ethylene
glycol, ammonium fluoride, and DL-Lactic acid (Sigma-
Aldrich), as described previously.16,17 Special temperature-
controlled electrochemical apparatus was set up using
anodization conditions at 60°C and 120 V for 5 minutes.
Subsequently, the TNT layer was removed by sonication in
methanol, and the second anodization was carried out under
similar conditions to prepare well-defined TNT/Ti. We chose
the dimensions of nanoimplants based on our previous studies
that have also undertaken detailed characterization using var-
ious methods, including scanning electron microscopy, X-ray
power diffraction, and contact angle measurement.16,17
Protein loading and polymer coating
GPC3 and BSA were loaded into the nanotubes using a
vacuum drying technique (5 µg/sample). The amount of pro-
tein was determined from our observation of the amount
required to show optimal regulatory effect of glypicans on
the BMP pathway within therapeutic limit.2,16 Nanotube
arrays were surface coated with 2% chitosan solution (spin-
Wildtype model
(proof of principle)




TNT/Ti loaded with inhibitor




















Ti/TNT or proteins) 
(n=6)
Figure 2 Flowchart showing the experimental layout (study design) for different TNT/Ti treatment groups at two different stages: (A) first stage of implant testing in Wildtype
mice (proof of principle) to refine the delivery method, and (B) second stage of translating the refined drug delivery system into the Crouzon murine model (study aim).
Abbreviations: TNT/Ti, Titania nanotubular implant; BSA, bovine serum albumin; GPC3, glypican 3 protein.
Bariana et al Dovepress
submit your manuscript | www.dovepress.com
DovePress





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
coated at 1500 rpm for 15 seconds) for five wildtype mice and
12 Fgfr2c342y/+ knock-in mice (Figure 2). We used a field-
emission scanning electron microscope for morphological
characterization of implants (FEI Quanta 450, Eidenhoven,
the Netherlands). Prior to animal experiments, the protein-
loaded implants were sterilized using low-temperature hydro-
gen peroxide gas plasma (STERRAD® 100 NXTM System,
Advanced sterilization Products, Irvine, CA, USA).
Surgical procedure
The mice were anesthetized by injecting a mixture of 100 mg/
kg ketamine hydrochloride and 10 mg/kg xylazine via intraper-
itoneal route, followed by subcutaneous injection of 0.05mg/kg
of the analgesic, buprenorphine. Once unresponsive to paw-
pinching, the eyes were protected by lacrilube to prevent cor-
neal damage. The hair on the scalp was disinfected using 70%
ethanol, and a C-shaped incision was made on the skin over the
parietal bone. The skin flap was gently lifted to expose the
cranium and a 3 mm circular CSD was created using a fine
biopsy puncture lateral to the right coronal suture with contin-
uous saline buffer irrigation under well-lit condition. The bone
disc (from the CSD) was removed gently, ensuring that the
underlying dura remained intact. The sterilized protein-loaded
TNT/Ti were carefully inserted into the CSD. After craniect-
omy and implantation, the surgical sites were sutured and the
mice were allowed to recover on a heat pad/incubator or held in
the palm of hand to establish rhythmic breathing before being
transferred into individual cages. The mice were assessed for
any skin reaction over the implant, weight loss, or distress twice
daily for 3 months. Histological analysis in a separate sample
showed that there was no adverse reaction, including necrosis,
lipoma formation, subdural hematoma, or chronic inflammation
(eg, influx of macrophages, giant cells, or neutrophils) on the
skin or bone over the implantation site (unpublished data).
Assessment of bone regeneration
At 90 days post-operatively (post-implantation period), the
mice were euthanized by asphyxiation with carbon dioxide
(at a flow rate of 0.5%). The skulls were dissected from
the soft tissues and the implant discs removed carefully so
that the surgical procedure did not cause any damage to
the underlying bone and other tissues. Then, the skulls
were subjected to micro-CT imaging (Skyscan 1076
small animal micro-CT, Bruker, Kontich, Belgium) using
these parameters: 50 kV, 110 µA with a rotation step of
0.6, 0.5 mm Al filter, scanning width of 35 mm, imaging
time of 48 minutes, and image resolution of 8.7 µm. We
used Skyscan NRecon software for image reconstruction
as BMP files (ring artefact correction of 15, beam hard-
ening correction of 30%, smoothing at 1 pixel, misalign-
ment correction of <10, and thresholding limits of 0.00–
0.11). We used Data viewer, CTan, and Aviso 9.0 software
for realignment, segmentation, 3D image reconstruction,
and morphometric analysis. We calculated the volume of
newly formed bone in each CSD by creating a 3 mm wide
cylindrical volume of interest at the centre of each recon-
structed CSD axially over the entire bone thickness. The
ratio of the bone volume to the total tissue volume in the
CSD provided the percentage bone volume data. We did
not use medication such as tetracycline antibiotic that
could have affected bone metabolism.
Histological analysis was carried out by decalcifying
the cranium with 10% EDTA in 0.1 M Tris Buffer (pH
7.4) and 7% sucrose for up to 4 weeks at room tem-
perature, followed by embedding in paraffin wax. The
sections were then cut into 7 µm thick serial sagittal
slices using a rotary microtome (Leica Microsystems,
Wetzlar, Germany). Sagittal sections were made around
each CSD and then stained with H&E and Movat
Pentachrome stains using standard protocols. The slides
were imaged using a bright field microscope (Carl Zeiss,
Jena, Germany), equipped with a DFC480 digital cam-
era (Leica Microsystems).
Statistical analysis
Statistical analysis was conducted using the IBM SPSS
Statistics software (version 26) (IBM Corporation,
Armonk, NY, USA). The Shapiro-Wilk test confirmed
normal distribution of the bone volume percentage data.
One-way ANOVA and Bonferroni’s post-hoc tests were
carried out separately for the wildtype and Crouzon mod-
els to assess whether bone volume percentage (outcome)
varied significantly between treatment groups (variables).
Statistical significance was set at the 0.05 probability level.
Statistical interpretation was made by taking into account
both the P-values and effect size (Cohen’s f). Effect size
was calculated by using the formula: f=√(ƞ2/(1–ƞ2)),
where ƞ2 (partial ita-squared) was obtained as a
MANOVA output. The effect size (f) of 0.10 is mild,
0.25 is moderate, and 0.40 is high.
Results
Characterization of fabricated TNT/Ti
The typical structure of fabricated TNTs/Ti implant is pre-
sented in SEM images in Figure 3 (the whole implant disc in A
Dovepress Bariana et al
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and TNT structure at different magnifications in B and C).
These images showed well-adhered, hexagonally arranged,
and densely packed Titania nanotubes with average diameter
of 120±10 nm even after being implanted in CSDs for 90 days,
indicating that the nanotubular architecture was well-pre-
served with ordered arrays of open-pored structure.
However, the nanotube wall was rough and flaky at the top,
probably because of implant interaction with fibrous tissue/
protein from the extracellular matrix within the CSD.We only
observed minor superficial wound infection at the incision site
(away from the implant) in two mice that were treated with a
short course of oral tetracycline for 3 days. Although tetracy-
cline has been shown to accelerate bone healing, a short-term
treatment is unlikely to have caused major issues in our study.
There was no adverse reaction on the soft tissues or the bone
during the study period, indicating that the TNT/Ti, proteins,
and chitosan coating were biocompatible.
Protein release in the wildtype model
The 3D micro-CT reconstructions and 2D sagittal sections of
CSDs inwildtype skulls at day 90 post-operatively are shown in
Figures 4A and B. The BSA-loaded CSDs, either with or with-
out chitosan-coating, displayed some reossification. In contrast,
GPC3 treated CSDs were larger, with less bone formation over
the duramater. One-wayANOVA showed a significant effect of
the treatment on bone volume percentage (P<0.01), and
Bonferroni post-hoc tests revealed a significantly lower bone
volume percentage for the GPC3-treated CSD (TNT-GPC3)
than either of the twoBSA-treatedCSDwithorwithout chitosan
coating (TNT-BSA-CH or TNT-BSA) (P<0.01 for each com-
parison; effect size=1.1 (large) and 1.2 (large), respectively)
(Figure 4C). These findings provided proof of principle valida-
tion that GPC3-loaded TNT/Ti can therapeutically downregu-
late the BMP2 activity and inhibit bone regeneration in vivo.
The micro-CT data was consistent with histological ana-
lysis (Figures 4 and 5). The H&E staining for the BSA
groups showed prominent bone reossification and defect
healing (with thick acellular fibrous tissue) in both uncoated
and chitosan-coated TNT/Ti (implantation sites), with the
latter displaying isolated bony islands interpolating the
fibrous tissue inside the defect. GPC3-treated CSDs showed
larger, unhealed, and less ossified (fibrous) defect sites com-
pared with the BSA-treated groups, confirming inhibition of
bone regeneration by GPC3-loaded TNT/Ti.
Protein release in the Crouzon murine
model
The 3D micro-CT reconstructions and 2D sagittal sections
of CSDs are shown in Figures 6A and B. The micro-CT
images showed near obliteration of CSDs in the control
group due to accelerated bone morphogenesis associated
with the Fgfr2c342y/+ knock-in mutation. One-way
ANOVA showed a significant effect of the GCP3 treat-
ment (either with or without chitosan coating) on bone
volume percentage (Figure 6C). Bonferroni’s post-hoc
tests revealed a significantly lower bone volume percen-
tage for the GPC-treated CSD without chitosan (TNT-
GPC3) compared with the craniectomy control (P<0.001,
effect size=0.86 (large)), and for the GPC-treated CSD
without chitosan (TNT-GPC3) compared with the GPC-
treated CSD with chitosan (TNT-GPC3-CH) (P<0.05,
effect size=0.57 (large)).
Histological findings were consistent with the micro-CT
data (Figure 7). The H&E and Movat Pentachrome staining
of the control CSDs mainly exhibited mature lamellar bone
and a thick band of fibrous tissue bridging the gaps at a low
magnification (×4). The high magnification images (×20)
displayed newly regenerated bony edges with ectopic bony
islands interweaved within the collagen fibres. Chitosan coat-
ing in GPC3-loaded nanotubes resulted in incomplete heal-
ing with ectopic bone formation, with a trend of relatively
greater bone regeneration in coated than uncoated nanotubes.
Figure 3 SEM images showing the surface topography of representative TNT/Ti delivery platforms after day 90 of the in vivo study showing (A) the whole fabricated implant disc
with TNT structures, and (B–C) only the TNT structures (top view) at different magnifications.
Abbreviations: TNT/Ti, Titania nanotubular implant; TNT, Titania nanotube.
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Discussion
Our results prove our hypothesis of inhibition of cranial bone
regeneration in Fgfr2c342y/+ knock-in mice by GPC3-loaded
TNT/Ti. Given that existing in vitro, ex vivo, and in vivo
studies on these implants (for dental and orthopedic applica-
tions) are at an early stage of research and development, our
pre-clinical study is a major advance in the novel field of
minimally-invasive craniosynostosis therapy and holds the
prospect of clinical translation to reduce the morbidity and
mortality in affected children. This nanoimplant system also
has additional potential craniofacial applications, including
orthopedic correction of malocclusion (eg, maxillary expan-
sion by releasing fused mid-palatal suture) and correction of
various skeletal defects (eg, in hemifacial macrosomia). Such
drug delivery systems will require precise control over the
release of various drugs that promote and inhibit bone regen-
eration. This approach could also benefit prolonged, sustained
delivery of antimicrobial and remineralizing agents intraorally,
such as dental caries and erosion.
Various nano-drug delivery systems, including those
based on natural or synthetic polymeric, metallic, and
organic nanoparticles, have been explored for clinical
application.27–31 In craniofacial clinical practice, the TNT-
based implant system is likely to have an advantage over its
zero-dimensional counterparts (quantum dots, nanoclusters,

































Morphometric analysis of CSDs in wildtype mice
*
* *
Figure 4 Micro-CT images and bone volume percentage data for newly formed bone in wildtype mice treated with non-functional BSA protein (either with chitosan coating [TNT-BSA-
CH] or no coating [TNT-BSA]), and GPC3 protein (TNT-GPC3) at day 90 post-operatively; (A) Top view of the 3D micro-CTreconstructions showing surgically created critical-sized
defects (CSDs), (B) Sagittal sections through themiddle of theCSDs , and (C) bone volume percentagewithin a 3mmwide cylindrical volumeof interest around theCSDs. * and ** indicate
significant differences at P<0.01 between the TNT-GPC3 group and the TNT-BSA-CH group, and the TNT-GPC3 group and the TNT-BSA group, respectively. There was no significant
difference in bone volume percentage between the TNT-BSA-CH and TNT-BSA groups. Effect size: TNT-GPC3 vs TNT-BSA-CH=1.13 (large); TNT-GPC3 vs TNT-BSA=1.20 (large).
Abbreviations: BSA, bovine serum albumin; BV, bone volume; CH, chitosan; GPC3, glypican 3 protein; Ti, titanium; TNT, Titania nanotube; TV, total volume; WT, wildtype.
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blood–brain barrier (due to relatively high aspect ratio).27
Traditionally, TNTs have been believed to be mechanically
robust, non-toxic, and chemically stable/inert and stable in
vivo.32 After drug delivery is complete, the TNT/Ti may not
require surgical removal, just as titanium plates and screws
used for surgical repair of fractured bones are left in place in
the long-term. However, there is some emerging evidence to
suggest potential issues with peri-implant and orthopedic
complications associated with metal release.33 Long-term
immune response to nano-drug delivery systems remains a
largely unexplored area,34 and further research is needed to
investigate this.
We designed TNT/Ti specially for easy insertion into the
3 mm wide CSD, without damaging the nanotube arrays.
While our previous in vitro study showed glypican release
from TNT/Ti for around 2 weeks in buffer,16 the release
duration is likely to be prolonged in our current study (evi-
denced by decrease in bone regeneration), probably because
of a limited diffusion gradient in vivo. In uncoated TNT/Ti,
proteins are released into the CSD and the perisutural region
by passive diffusive transport in the cranial environment
(extracellular matrix and interstitial fluids).35 In comparison,
the release kinetics of the proteins in chitosan-coated TNT/Ti
(polymer thickness ~1 µm) is modified by polymer
degradation and transformation.16,17 Chitosan undergoes
slow enzymatic hydrolysis in the presence of several pro-
teases, mainly lysozymes (present in body fluids), which
contributes to prolonged drug release,36 and partially open
pores (with patches of undissolved polymer) have been
shown to be responsible for sustained drug release.37 There
was some trend of less bone regeneration in the TNT-GPC3-
CH group compared with the control group in the Crouzon
murine model, but it did not reach statistical significance.
Further study is indicated using a larger sample size to
investigate this.
Our observation of near obliteration of the CSD in
Crouzon murine model is consistent with accelerated
bone regeneration after craniectomy in a patient with cor-
onal synostosis (without any bone graft).38 In contrast,
GPC3 releasing implants (chitosan-coated and uncoated
TNTs) reduced re-ossification at the craniectomy site,
with the chitosan-coated implants, demonstrating a greater
number of bony islands over the dura than uncoated
implants (Figures 6 and 7). Our observation of reduced
bone formation in chitosan-coated GPC3 nanoimplants can
be attributed to non-uniform degradation of chitosan by
lysozymes in the cranial environment (failing to provide
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Figure 5 Histological (H&E) images showing bone regeneration in the critical-sized defects (CSDs) of the three wildtype groups at day 90 post-operatively at (A) a low
magnification (×4) and (B) a high magnification (×20). Images A and B were prepared from different slices of the same CSD (for each group) that displayed the features most
clearly at each magnification. Black arrows mark the new bone edge.
Notes: WT-TNT-BSA-CH, wildtype mice in which Titania nanotubes were loaded with bovine serum albumin and also coated with chitosan; WT-TNT-BSA, Wildtype mice
in which Titania nanotubes were loaded with bovine serum albumin but not coated with chitosan; WT-TNT-GPC3, Wildtype mice in which Titania nanotubes were loaded
with glypican 3 protein.
Abbreviations: nb, new bone; ft, fibrous tissue; TNT, Titania nanotube (delaminated); WT, wildtype; BSA, bovine serum albumin; TNT, Titania nanotube; CH, chitosan;
GPC3, glypican 3 protein.
Bariana et al Dovepress
submit your manuscript | www.dovepress.com
DovePress





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
might have occurred centripetally towards the chitosan
surfaces. Even with a low degree of acetylation, the posi-
tively charged coating could have stimulated osteoblast
adhesion and differentiation that are evident in the form
of bony islands.40,41 However, it appears to have been
counteracted by inhibition of bone development by
GPC3 (Figures 4 and 5).
Future animal studies on a larger sample are indicated to
refine the dosage and duration of the TNT/Ti drug delivery
system (at various time periods) on various age groups and
both sexes, which will provide a sound foundation to conduct
human clinical trials. Clinically, TNTs can be fabricated
easily on metal/3D printed fixation devices used in surgical
procedures (eg, bone plates and screws). Ultimately, success-
ful clinical translation could alter the whole paradigm of
treatment for children affected by craniosynostosis.
Conclusion
Ease of fabrication, physiologically relevant nano-archi-
tecture, and the capability for localized protein delivery
make TNT/Ti an attractive option for craniofacial drug


































Morphometric analysis of  CSDs in crouzon mice
*
* *
Figure 6 Micro-CT images and bone volume percentage data for newly formed bone in three groups of the Crouzon murine model (with Fgfr2c342y/+ knock-in mutation)
including the surgical control (craniectomy only) and the two experimental groups, including Titania nanotubes loaded with glypican 3 protein and then either coated with
chitosan (TNT-GPC3-CH) or not (TNT-GPC3), at day 90 post-operatively; (A) Top view of the 3D reconstructed skulls from micro-CT scans showing surgically created
critical-sized defects (CSDs), (B) Sagittal sections through the middle of the CDSs, and (C) bone volume percentage within a 3 mm wide cylindrical volume of interest
around the CSDs. *Significant difference between the TNT-GPC3 group and the control group at P<0.001, and **Significant difference between the TNT-GPC3 group and
the TNT-GPC3-CH group at P<0.05. There was no significant difference in bone volume percentage between the control and TNT-GPC3-CH groups. Effect size: TNT-GPC3
vs control=0.86 (large); TNT-GPC3 vs TNT-GPC3-CH=0.57 (large). CZ represents Crouzon murine model in image A.
Abbreviations: BV, bone volume; CH, chitosan; GPC3, glypican 3 protein; TNT, Titania nanotube; TV, total volume.
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demonstrates the effectiveness of TNT/Ti delivery systems
in inhibiting bone regeneration in a Crouzon murine model
of craniosynostosis. This minimally invasive non-surgical
adjuvant holds the prospect of clinical translation in treat-
ing affected children, improving the likelihood of reducing
the morbidity and mortality associated with repeated cra-
nial vault reconstruction.
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